Thierry Berghmans

Summary

Affiliation: Institut Jules Bordet
Country: Belgium

Publications

  1. ncbi request reprint An ELCWP phase III trial comparing ifosfamide and cisplatin regimens in advanced NSCLC
    Thierry Berghmans
    Institut Jules Bordet, Rue Heger Bordet, 1, B 1000 Brussels, Belgium
    Anticancer Res 33:5477-82. 2013
  2. doi request reprint Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study
    T Berghmans
    Department of Oncological Intensive Care and Emergencies and Thoracic Oncology, Universite Libre de Bruxelles ULB, Brussels, Belgium Electronic address
    Lung Cancer 82:340-5. 2013
  3. ncbi request reprint Final results and pharmacoeconomic analysis of a trial comparing two neoadjuvant chemotherapy (CT) regimens followed by surgery in patients with resectable non-small cell lung cancer (NSCLC): a phase II randomised study by the European Lung Cancer Working
    T Berghmans
    Department of Intensive Care and Thoracic Oncology, Institut Jules Bordet, Brussels, Belgium
    Lung Cancer 77:605-10. 2012
  4. pmc Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis
    A P Meert
    Service de Medecine, Institut Jules Bordet, Bruxelles, Belgique
    BMC Cancer 1:5. 2001
  5. doi request reprint Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations
    T Berghmans
    Service des Soins Intensifs and Oncologie Thoracique, Institut Jules Bordet, Centre des Tumeurs de l Universite Libre de Bruxelles, 1 rue Héger Bordet, B 1000 Bruxelles, Belgium
    Eur Respir J 39:9-28. 2012
  6. ncbi request reprint A prospective study of infections in lung cancer patients admitted to the hospital
    Thierry Berghmans
    Service de Médecine et Laboratoire d Investigation Clinique H J Tagnon, Institut Jules Bordet, Centre des Tumeurs de l Universite Libre de Bruxelles, Brussels, Belgium
    Chest 124:114-20. 2003
  7. doi request reprint A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer
    T Berghmans
    Department of Intensive Care Unit and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l Université Libre de Bruxelles ULB, Brussels, Belgium
    Lung Cancer 64:187-93. 2009
  8. ncbi request reprint [Early-stage NSCLC. Resectable non-small cell lung cancers: (neo) adjuvant chemotherapy]
    T Berghmans
    Département des Soins Intensifs et Oncologie Thoracique, Institut Jules Bordet Centre des Tumeurs de l Université Libre de Bruxelles, 1 rue Héger Bordet, Brussels, Belgium
    Rev Mal Respir 25:3S72-8. 2008
  9. doi request reprint Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lu
    Thierry Berghmans
    Department of Intensive Care Unit and Thoracic Oncology, Institut Jules Bordet, Universite Libre de Bruxelles ULB, Bruxelles, Belgium
    J Thorac Oncol 3:6-12. 2008
  10. ncbi request reprint Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature
    T Berghmans
    Department of Intensive Care and Thoracic Oncology, Institut Jules Bordet, Rue Heger Bordet, 1 1000 Bruxelles, Belgium
    Lung Cancer 49:13-23. 2005

Detail Information

Publications68

  1. ncbi request reprint An ELCWP phase III trial comparing ifosfamide and cisplatin regimens in advanced NSCLC
    Thierry Berghmans
    Institut Jules Bordet, Rue Heger Bordet, 1, B 1000 Brussels, Belgium
    Anticancer Res 33:5477-82. 2013
    ..We aimed to compare cisplatin-based chemotherapy to ifosfamide-gemcitabine (IG) with pre-defined second-line docetaxel...
  2. doi request reprint Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study
    T Berghmans
    Department of Oncological Intensive Care and Emergencies and Thoracic Oncology, Universite Libre de Bruxelles ULB, Brussels, Belgium Electronic address
    Lung Cancer 82:340-5. 2013
    ..3 months (95% CI 29.8-52.4) and 15.5 months (95% CI 9.1-22.8) (p < 0.001; hazard ratio 21.1, 95% CI 4.7-94.9)...
  3. ncbi request reprint Final results and pharmacoeconomic analysis of a trial comparing two neoadjuvant chemotherapy (CT) regimens followed by surgery in patients with resectable non-small cell lung cancer (NSCLC): a phase II randomised study by the European Lung Cancer Working
    T Berghmans
    Department of Intensive Care and Thoracic Oncology, Institut Jules Bordet, Brussels, Belgium
    Lung Cancer 77:605-10. 2012
    ..In conclusion, while both neoadjuvant chemotherapy regimens shared similar efficacy in patients with resectable NSCLC, costs were significantly higher for third-generation regimens...
  4. pmc Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis
    A P Meert
    Service de Medecine, Institut Jules Bordet, Bruxelles, Belgique
    BMC Cancer 1:5. 2001
    ..A systematic review of the literature was carried out to determine the role of prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC)...
  5. doi request reprint Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations
    T Berghmans
    Service des Soins Intensifs and Oncologie Thoracique, Institut Jules Bordet, Centre des Tumeurs de l Universite Libre de Bruxelles, 1 rue Héger Bordet, B 1000 Bruxelles, Belgium
    Eur Respir J 39:9-28. 2012
    ..Other criteria assessed in these recommendations are not currently adequate surrogates of survival in lung cancer...
  6. ncbi request reprint A prospective study of infections in lung cancer patients admitted to the hospital
    Thierry Berghmans
    Service de Médecine et Laboratoire d Investigation Clinique H J Tagnon, Institut Jules Bordet, Centre des Tumeurs de l Universite Libre de Bruxelles, Brussels, Belgium
    Chest 124:114-20. 2003
    ..To determine the type of infections occurring in hospitalized patients with lung cancer...
  7. doi request reprint A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer
    T Berghmans
    Department of Intensive Care Unit and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l Université Libre de Bruxelles ULB, Brussels, Belgium
    Lung Cancer 64:187-93. 2009
    ..Consolidation chemoradiotherapy seems less toxic with a better observed response rates and survival although no valid conclusion can be drawn from the comparison of both arms...
  8. ncbi request reprint [Early-stage NSCLC. Resectable non-small cell lung cancers: (neo) adjuvant chemotherapy]
    T Berghmans
    Département des Soins Intensifs et Oncologie Thoracique, Institut Jules Bordet Centre des Tumeurs de l Université Libre de Bruxelles, 1 rue Héger Bordet, Brussels, Belgium
    Rev Mal Respir 25:3S72-8. 2008
    ....
  9. doi request reprint Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lu
    Thierry Berghmans
    Department of Intensive Care Unit and Thoracic Oncology, Institut Jules Bordet, Universite Libre de Bruxelles ULB, Bruxelles, Belgium
    J Thorac Oncol 3:6-12. 2008
    ..Primary tumor standardized uptake value (SUV) has been studied as a potential prognostic factor for survival. However, the sample sizes are limited leading to conduct a meta-analysis to improve the precision in estimating its effect...
  10. ncbi request reprint Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature
    T Berghmans
    Department of Intensive Care and Thoracic Oncology, Institut Jules Bordet, Rue Heger Bordet, 1 1000 Bruxelles, Belgium
    Lung Cancer 49:13-23. 2005
    ..More data are needed to confirm such a role for induction chemotherapy. Further trials should separate stage III disease from earlier stages...
  11. doi request reprint EGFR, TTF-1 and Mdm2 expression in stage III non-small cell lung cancer: a positive association
    T Berghmans
    Department of Intensive Care Unit and Thoracic Oncology, Institut Jules Bordet, ULB Université Libre de Bruxelles, Bruxelles, Belgium
    Lung Cancer 62:35-44. 2008
    ..0004). In stage III NSCLC, there was a significant association between TTF-1 and EGFR or TTF-1 and Mdm2. The status EGFR+/TTF-1--was associated with squamous cell carcinoma...
  12. ncbi request reprint Is a specific oncological scoring system better at predicting the prognosis of cancer patients admitted for an acute medical complication in an intensive care unit than general gravity scores?
    T Berghmans
    Critical Care Department and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l Universite Libre de Bruxelles, Rue Heger Bordet, 1, 1000 Brussels, Belgium
    Support Care Cancer 12:234-9. 2004
    ....
  13. ncbi request reprint Continuous venovenous haemofiltration in cancer patients with renal failure: a single-centre experience
    T Berghmans
    Department of Internal Medicine, Institut Jules Bordet, Rue Heger Bordet 1, 1000, Brussels, Belgium
    Support Care Cancer 12:306-11. 2004
    ..To assess the effect of continuous venovenous hemodiafiltration (CVVHDF) in cancer patients with acute renal failure...
  14. ncbi request reprint Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis
    T Berghmans
    Department of Intensive Care and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l Universite Libre de Bruxelles, Belgium
    Ann Oncol 17:1673-6. 2006
    ..The aim of this study was to determine the prognostic role for survival of thyroid transcription factor 1 (TTF-1) in lung cancer...
  15. ncbi request reprint Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer
    T Berghmans
    Dept of Critical Care and Thoracic Oncology, Institut Jules Bordet, Rue Heger Bordet 1, 1000 Bruxelles, Belgium
    Eur Respir J 25:329-35. 2005
    ....
  16. ncbi request reprint Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy
    T Berghmans
    Department of Internal Medicine, Institut Jules Bordet, Rue Heger Bordet, 1 Bruxelles 1000, Belgium
    Lung Cancer 45:339-48. 2004
    ..11-1.99; P = 0.007) were found significant. In model 2, including ELCWP staging, two variables were associated with survival: ELCWP staging (HR 1.68; 95% CI 1.20-2.35; P = 0.002) and haemoglobin (HR 1.54; 95% CI 1.15-2.07; P = 0.01)...
  17. ncbi request reprint Prognostic role of p53 in stage III non-small cell lung cancer
    Thierry Berghmans
    Department of Critical Care and Thoracic Oncology, Institut Jules Bordet, Rue Heger Bordet, 1, Brussels, Belgium
    Anticancer Res 25:2385-9. 2005
    ..Materials and Methods: p53 expression was assessed by immunohistochemistry and evaluated by three independent observers. The Cox model was used to assess the impact of clinical and biological factors on patient survival...
  18. ncbi request reprint [News for lung cancer care]
    T Berghmans
    Département des Soins Intensifs et Oncologie Thoracique, Institut Jules Bordet, Centre des Tumeurs de l U L B, Bruxelles
    Rev Med Brux 30:287-91. 2009
    ....
  19. pmc Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party
    T Berghmans
    Department of Critical Care and Thoracic Oncology, Institut Jules Bordet, 1, Rue Heger Bordet, B 1000, Bruxelles, Belgium
    Br J Cancer 96:1644-9. 2007
    ..79, 95% CI 1.26-2.55; P=0.001). Paclitaxel in NSCLC patients, whether given for primary or for SF after cisplatin-based chemotherapy, demonstrates activity similar to other drugs considered active as second-line therapy...
  20. ncbi request reprint Mitomycin, ifosfamide, cisplatin for non-small cell lung cancer: an implementation study
    T Berghmans
    Department of Intensive Care Unit and Thoracic Oncology, Institut Jules Bordet, Brussels, Belgium
    Monaldi Arch Chest Dis 63:184-92. 2005
    ..The MIP regimen (mitomycin, ifosfamide, cisplatin) demonstrated its effectiveness as first-line chemotherapy in phase II and III trials in NSCLC. We aimed to determine whether these results could be confirmed in a hospital population...
  21. ncbi request reprint Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis
    T Berghmans
    Department of Internal Medicine, Institut Jules Bordet, Brussels, Belgium
    Support Care Cancer 10:181-8. 2002
    ..On the basis of this review, we cannot recommend the routine use of G-CSF or GM-CSF in established febrile neutropenia...
  22. ncbi request reprint A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma
    T Berghmans
    Department of Intensive Care and Thoracic Oncology, Institut Jules Bordet, Rue Heger Bordet 1, 1000 Bruxelles, Belgium
    Lung Cancer 50:75-82. 2005
    ..In conclusion, cisplatin plus epirubicin appears as an effective regimen in malignant mesothelioma, with a favourable toxicity profile. However, it does not demonstrate superior activity to other active regimens in this disease...
  23. ncbi request reprint Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis
    T Berghmans
    Department of Internal Medicine, Institut Jules Bordet, Rue Heger Bordet 1, 1000 Bruxelles, Belgium
    Lung Cancer 37:115-23. 2002
    ..In conclusion, the published data do not support the routine use of haematological colony-stimulating factors in the treatment of small-cell lung cancer (SCLC)...
  24. ncbi request reprint Prognostic role of thyroid transcription factor-1 in stage III non-small cell lung cancer
    T Berghmans
    Department of Intensive Care Unit and Thoracic Oncology, Institut Jules Bordet, Bruxelles, Belgium
    Lung Cancer 52:219-24. 2006
    ..Forty-four patients were positive for TTF-1 (squamous 25.0% versus non-squamous 55.4%). In multivariate analysis, only three factors were statistically significantly associated with better survival: good PS, surgery and creatinine level...
  25. ncbi request reprint Correction of hyponatremia by urea in a patient with heart failure
    T Berghmans
    Département de Soins Intensifs et Oncologie Thoracique, Institut Jules Bordet, Bruxelles, Belgique
    Acta Clin Belg 60:244-6. 2005
    ..Profound hyponatremia in the context of symptomatic heart failure was documented. Intravenous infusion of NaCl 0.9% was unsuccessful. Treatment with oral urea was begun and sodium level returned to nearly normal values 5 days later...
  26. ncbi request reprint Vibrio cholerae bacteremia in a neutropenic patient with non-small-cell lung carcinoma
    T Berghmans
    Department of Internal Medicine, Institut Jules Bordet, Rue Heger Bordet 1, 1000 Brussels, Belgium
    Eur J Clin Microbiol Infect Dis 21:676-8. 2002
    ..Although Vibrio spp. have occasionally been the source of infection in immunocompromised patients, this report describes the first case of non-0:1 Vibrio cholerae bacteremia in a neutropenic patient with a solid tumour...
  27. ncbi request reprint Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis
    T Berghmans
    Service do Médecine Interne et Laboratoire d Investigation Clinique et d Oncologie Expérimentale, Institut Jules Bordet, Centre des Tumeurs de I Université Libre de Brussels, Rue Heger Bordet, 1, 1000 Brussels, Belgium
    Lung Cancer 38:111-21. 2002
    ..The combination of these two drugs can be recommended as control arm for future randomised phase III trials...
  28. ncbi request reprint Age and treatment of non-small-cell lung cancer: a database analysis in elderly patients
    T Berghmans
    Department of Internal Medicine, Institut Jules Bordet, Rue Heger Bordet, 1, 1000 Brussels, Belgium
    Support Care Cancer 10:619-23. 2002
    ..Because the number of patients was too small, our data do not allow us to provide meaningful conclusions for stage IV disease...
  29. doi request reprint Mitomycin plus vinorelbine salvage chemotherapy in non-small cell lung cancer: a prospective study
    Thierry Berghmans
    Department of Intensive Care Unit and Thoracic Oncology, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Lung Cancer 61:378-84. 2008
    ..3 weeks (p=0.16). In conclusion, mitomycin-vinorelbine combination is a moderately active regimen in heavily pre-treated patients with NSCLC relapsing or progressing after taxanes and platinum-based chemotherapy. Its toxicity is limited...
  30. doi request reprint Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Part
    Marianne Paesmans
    Data Centre, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Thorac Oncol 5:612-9. 2010
    ..The prognostic value of this lung tumor metabolic activity was studied in a first systematic review of studies published until 2006...
  31. ncbi request reprint A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. European Lung Cancer Workin
    J P Sculier
    Service de Medecine, Institut Jules Bordet, Brussels, Belgium
    Ann Oncol 10:295-303. 1999
    ....
  32. pmc Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer
    J P Sculier
    , For the European Lung Cancer Working Party, Institut Jules Bordet, , Brussels, B 1000, Belgium
    Br J Cancer 83:1128-35. 2000
    ..The results support the use of a moderate dose (50 mg m(-2)) of cisplatin in combination with ifosfamide and mitomycin for the chemotherapy of this disease...
  33. ncbi request reprint C-erbB-3 expression in non-small cell lung cancer (NSCLC) patients treated by Erlotinib
    Ingrid Cstoth
    Département d Oncologie Thoracique et Soins Intensifs et Data Centre, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Anticancer Res 31:281-5. 2011
    ..The clinical impact of c-erbB-3 has seldom been assessed in patients with non small cell lung cancer (NSCLC)...
  34. pmc A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics
    J P Sculier
    Department of Medicine, Institut Jules Bordet, , B 1000 Bruxelles, Belgium
    Br J Cancer 85:1444-51. 2001
    ..Non-severe infections were more frequent in arm B and severe infections were less frequent in arm C. Our trial failed to demonstrate, in ED-SCLC, a survival benefit of chemotherapy acceleration by using GM-CSF support...
  35. ncbi request reprint [Adjuvant treatments of non-small cell lung cancer]
    L Moretti
    Département de Radio Oncologie, Institut Jules Bordet, 121, boulevard de Waterloo, 1000 Bruxelles, Belgique
    Cancer Radiother 11:53-8. 2007
    ..The role of radiotherapy is still controversial but from some clinical observations, a new trial using the modern radiation technology should address the question...
  36. ncbi request reprint Non-invasive ventilation for cancer patients with life-support techniques limitation
    Anne Pascale Meert
    Department of Intensive Care and Thoracic Oncology, Institut Jules Bordet, Brussels, Belgium
    Support Care Cancer 14:167-71. 2006
    ....
  37. ncbi request reprint Leucopenia is an independent predictor in cancer patients requiring invasive mechanical ventilation: a prognostic factor analysis in a series of 168 patients
    F Vallot
    Department of Medicine and Data Centre Biostatistics Unit, Institut Jules Bordet, Centre des Tumeurs de l Universite Libre de Bruxelles, Bruxelles, Belgium
    Support Care Cancer 11:236-41. 2003
    ..To determine prognostic factors predicting success of invasive mechanical ventilation in medical cancer patients admitted to ICU for a complication, in terms of extubation and ICU and hospital discharges...
  38. ncbi request reprint Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer
    Anne Pascale Meert
    Fonds National de la Recherche Scientifique, Belgium
    Lung Cancer 44:295-301. 2004
    ..The PPV of the B was 96%. In conclusion, biopsies may provide reliable information about p53, EGF-R, c-erbB-2 and Ki-67 in lung carcinoma and could help to elaborate a therapeutic strategy...
  39. ncbi request reprint A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer
    J P Sculier
    Institut Jules Bordet, Department of Intensive Care and Thoracic Oncology, Brussels, Belgium
    Ann Oncol 18:1037-42. 2007
    ....
  40. doi request reprint A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer
    J P Sculier
    Institut Jules Bordet, Brussels, Belgium
    Ann Oncol 19:1691-7. 2008
    ....
  41. ncbi request reprint [Indications and results of intensive care in patients with lung cancer]
    J P Sculier
    Unité de Soins Intensifs Médico Chirurgicaux et Oncologie Thoracique, Institut Jules Bordet, Universite Libre de Bruxelles, Belfique
    Rev Mal Respir 24:6S114-9. 2007
    ..This would appear to justify the application of life-supporting techniques in patients where there is the potential for ongoing anti-cancer treatment...
  42. ncbi request reprint Chemotherapy improves low performance status lung cancer patients
    J P Sculier
    Dept of Critical Care and Thoracic Oncology, Institut Jules Bordet, 1 rue Héger Bordet, B 1000 Bruxelles, Belgium
    Eur Respir J 30:1186-92. 2007
    ..2 versus 2.1%). In conclusion, combination chemotherapy is associated with clinical improvement in a substantial number of patients with advanced nonsmall cell lung cancer of poor performance status...
  43. ncbi request reprint [Other thoracic cancers. Mesothelioma: treatment]
    T Berghmans
    Département des Soins Intensifs et Oncologie Thoracique, Institut Jules Bordet Centre des Tumeurs de l Université Libre de Bruxelles, 1 rue Héger Bordet, Brussels, Belgium
    Rev Mal Respir 25:3S191-5. 2008
    ..There are few active cytotoxic drugs in this disease. Currently, based on two randomised trials, the most efficacious chemotherapy regimen consists in a combination of cisplatin and an antifolate agent, pemetrexed or raltitrexed...
  44. ncbi request reprint Hypothermia and Hodgkin's disease: case report and review of the literature
    A P Meert
    Department of Intensive Care and Thoracic Oncology, Institut Jules Bordet, Brussels, Belgium
    Acta Clin Belg 61:252-4. 2006
    ..We also reviewed the 12 other cases of hypothermia in Hodgkin's disease reported in the literature and discussed the most probable physiopathologic aetiologies...
  45. ncbi request reprint Citation indexes do not reflect methodological quality in lung cancer randomised trials
    T Berghmans
    Department of Internal Medicine, Institut Jules Bordet, Bruxelles, Belgium
    Ann Oncol 14:715-21. 2003
    ..Material and methods All of the randomised trials included in nine systematic reviews performed by the European Lung Cancer Working Party (ELCWP) were assessed using two quality scales (Chalmers and ELCWP)...
  46. ncbi request reprint [Mechanical ventilation in the cancer patient]
    J P Sculier
    Clinique des soins intensifs oncologiques et de la cancérologie pulmonaire, Institut Jules Bordet, Centre des Tumeurs de l Universite Libre de Bruxelles, 1000 Bruxelles, Belgique
    Rev Mal Respir 18:137-54. 2001
    ..Finally, we propose guidelines for a practical approach to this type of patient taking into account the prognosis and new techniques such as noninvasive ventilation...
  47. ncbi request reprint The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis
    A P Meert
    Dept of Internal Medicine, Jules Bordet Institute, Brussels, Belgium
    Eur Respir J 20:975-81. 2002
    ..Epidermal growth factor receptor might be a poor prognostic factor for survival in nonsmall-cell lung cancer. The amplitude of the impact is small, however, and may be subject to publication bias...
  48. pmc Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis
    B Martin
    Laboratoire d Investigation Clinique H J Tagnon, Departement de Medecine, Institut Jules Bordet Brussels, Belgium
    Br J Cancer 89:55-64. 2003
    ..26 (0.58-2.72) for three studies on neuroendocrine tumours. In NSCLC, Bcl-2 expression was associated with a better prognosis. The data on Bcl-2 expression in small cell lung cancer were insufficient to assess its prognostic value...
  49. pmc The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature
    A P Meert
    Fonds National de la Recherche Scientifique, Bruxelles, Belgium
    Br J Cancer 89:959-65. 2003
    ....
  50. ncbi request reprint A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer
    J P Sculier
    Department of Medicine, Institut Jules Bordet, Bruxelles, Belgium
    Ann Oncol 13:1454-9. 2002
    ..A phase II randomised trial was performed with patients with SCLC to determine if the addition of carboplatin to cisplatin-etoposide might improve the response rate in second-line therapy...
  51. pmc Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis
    B Martin
    Critical Care Department and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l Universite Libre de Bruxelles, Brussels, Belgium
    Br J Cancer 91:2018-25. 2004
    ..56 (95% CI: 1.30-1.87), showing a worse survival when Ki-67 expression is increased. In conclusion, our meta-analysis shows that the expression of Ki-67 is a factor of poor prognosis for survival in NSCLC...
  52. pmc The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis
    C Mascaux
    Department of Intensive Care and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l Universite Libre de Bruxelles, Belgium
    Br J Cancer 92:131-9. 2005
    ..40; 95% CI 1.18-1.65) but not in studies using IHC (HR 1.08; 95% CI 0.86-1.34). RAS appears to be a pejorative prognostic factor in terms of survival in NSCLC globally, in ADC and when it is studied by PCR...
  53. ncbi request reprint A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer
    J P Sculier
    Institut Jules Bordet, Bruxelles, Belgium
    Ann Oncol 13:874-82. 2002
    ....
  54. ncbi request reprint [Ovarian metastasis and lung adenocarcinoma: a case report]
    P Castadot
    Service de Radiotherapie, Institut Jules Bordet, 121, boulevard de Waterloo, 1000 Bruxelles, Belgique
    Cancer Radiother 9:183-6. 2005
    ..In conclusion, in the differential diagnosis of an ovarian metastasis, clinicians should not forget the lung as primary site since epidemiologic data of lung cancer in women show progressive incidence...
  55. pmc Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results
    C Mascaux
    Department of Intensive Care and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l Universite Libre de Bruxelles, B 1000 Brussels, Belgium
    Br J Cancer 95:139-45. 2006
    ..This effect is statistically significant in stage I, suggesting that COX-2 expression could be useful at early stages to distinguish those with a worse prognosis...
  56. ncbi request reprint A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer
    J P Sculier
    Institut Jules Bordet, Brussels, Belgium
    Ann Oncol 15:399-409. 2004
    ....
  57. ncbi request reprint A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy
    J P Sculier
    Department of Medicine, Institut Jules Bordet, 1, Rue Heger Bordet, B 1000, Brussels, Belgium
    Lung Cancer 37:73-7. 2002
    ..Median survival duration was 4.5 months with a 1-year rate at 19%. We concluded that paclitaxel is not active in terms of response as second-line chemotherapy for NSCLC...
  58. ncbi request reprint Noninvasive ventilation: application to the cancer patient admitted in the intensive care unit
    A P Meert
    Clinique des soins intensifs oncologiques et de la cancérologie pulmonaire, Départment de Médicine Interne, Institut Jules Bordet, Centre des Tumeurs de l Universite Libre de Bruxelles, Brussels, Belgium
    Support Care Cancer 11:56-9. 2003
    ..NIV thus appears to be an effective form of ventilatory support for cancer patients, including those with solid tumours...
  59. ncbi request reprint Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis
    E Steels
    , Institut Jules Bordet, , Brussels, Belgium
    Eur Respir J 18:705-19. 2001
    ..Data were insufficient to determine the prognostic value of p53 in small cell lung cancer. In each subgroup of nonsmall cell lung cancer, p53 abnormal status was shown to be associated with a poorer survival prognosis...
  60. doi request reprint Updates in oncology
    Jean Paul Sculier
    Service des Soins Intensifs et Urgences Oncologiques, Unité de recherche en oncologie thoracique, Institut Jules Bordet, Centre des Tumeurs de l Université Libre de Bruxelles ULB, Brussels, Belgium
    Eur Respir Rev 23:69-78. 2014
    ..Various topics were reviewed, including: epidemiology, screening, histology, and treatment of nonsmall cell lung cancer and small cell lung cancer. ..
  61. pmc Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables
    Thierry Berghmans
    Institut Jules Bordet, Rue Heger Bordet, 1, B 1000 Brussels, Belgium
    Ther Adv Med Oncol 3:127-38. 2011
    ..In conclusion, few PFs have been well evaluated in stage III NSCLC. New studies, taking into account the modifications derived from the 7th international staging system of the UICC, have to be performed...
  62. pmc The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis
    A P Meert
    Département de Médecine Interne et Laboratoire d Investigation Clinique et d Oncologie Expérimentale HJ Tagnon, Institut Jules Bordet, Bruxelles, Belgium
    Br J Cancer 87:694-701. 2002
    ..Microvessel count, reflecting the angiogenesis, appears to be a poor prognostic factor for survival in surgically treated non small cell lung cancer but standardisation of angiogenesis assessment by the microvessel count is necessary...
  63. ncbi request reprint [Cardiac arrest during TEP-scan]
    A Baize
    Département des Soins Intensifs et Oncologie Thoracique, Institut Jules Bordet, Bruxells
    Rev Med Brux 30:111-3. 2009
    ..A 72 year-old man presenting with a tonsil neoplasm developed a cardiac arrest when performing a positron emission tomography with tomodensitometry (18F-FDG-PET). The final diagnosis is obtained after interpretation of the PET-CT images...
  64. ncbi request reprint [Immune responses in broncho-pulmonary cancer]
    A P Meert
    Departement de Medecine Interne, HJ Tagnon, Institut Jules Bordet, Bruxelles, Belgique
    Rev Mal Respir 20:566-79. 2003
    ..The anti-tumoral immune response is essentially cellular and numerous studies have been conducted with the aim of augmenting it from the therapeutic aspect...
  65. ncbi request reprint [Chemotherapy of malignant pleural mesothelioma]
    T Berghmans
    Institut Jules Bordet, Bruxelles
    Rev Mal Respir 23:11S57-70. 2006
  66. ncbi request reprint Successful treatment of intractable hiccup with methylphenidate in a lung cancer patient
    R Marechal
    Department of Internal Medicine, Institut Jules Bordet, Centre des Tumeurs de l Universite Libre de Bruxelles, Brussels, Belgium
    Support Care Cancer 11:126-8. 2003
    ..It was rapidly efficient and well tolerated. This report suggests a potential advantage of MTP in the treatment of intractable hiccup in cancer patients...
  67. ncbi request reprint [Meningitis and renal cancer]
    N Amyai
    Département des Soins Intensifs et Clinique d Oncologie Thoracique, Institut Jules Bordet, Bruxelles
    Rev Med Brux 30:507-10. 2009
    ..Physical examination and blood analyses were not remarkable. Cerebral magnetic resonance imaging demonstrated radiological signs of meningitis. The differential diagnosis of meningitis is discussed...
  68. ncbi request reprint Second-line treatment for advanced non-small cell lung cancer: how to design a clinical trial for a new agent?
    Marianne Paesmans
    Lung Cancer 55:135-6. 2007